<DOC>
	<DOC>NCT02569996</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. The anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.</brief_summary>
	<brief_title>A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participants greater than (&gt;) 18 years of age Histologically confirmed follicular lymphoma Grade 1, 2, or 3a with lymph node biopsy within 4 months of induction treatment No previous antilymphoma treatment before induction chemotherapy (firstlinetreated participants only are eligible) Verified complete or partial remission after firstline induction therapy including rituximab Grade 3b follicular lymphoma Transformation to highgrade lymphoma (except to Grade 3a) of previously existing follicular lymphoma Presence of central nervous system lymphoma Acquired immunodeficiency syndromerelated lymphoma Other primary malignancy (other than squamous cell cancer of the skin or in situ cancer of the cervix) for which the participant has not been diseasefree for greater than or equal to (&gt;=) 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>